Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells 19,460 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 19,460 shares of the stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $14.68, for a total value of $285,672.80. Following the transaction, the chief operating officer owned 643,471 shares of the company’s stock, valued at $9,446,154.28. This represents a 2.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Julie Rubinstein also recently made the following trade(s):

• On Monday, March 9th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.79, for a total transaction of $457,617.39.
• On Tuesday, March 3rd, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.67, for a total transaction of $484,845.47.
• On Thursday, March 5th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.00, for a total value of $495,056.00.

Adaptive Biotechnologies Price Performance

Shares of Adaptive Biotechnologies stock traded down $0.43 on Tuesday, reaching $14.52. The company had a trading volume of 1,839,163 shares, compared to its average volume of 1,587,589. The firm has a market cap of $2.24 billion, a price-to-earnings ratio of -36.30 and a beta of 2.19. The firm’s 50-day moving average price is $16.72 and its two-hundred day moving average price is $15.88. Adaptive Biotechnologies Corporation has a 1 year low of $6.26 and a 1 year high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. The business had revenue of $71.68 million for the quarter, compared to analysts’ expectations of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The business’s revenue was up 51.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.23) earnings per share. As a group, analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ADPT. Guggenheim upped their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, January 26th. BTIG Research lifted their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Wall Street Zen downgraded shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, JPMorgan Chase & Co. increased their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $18.25.

Hedge Funds Weigh In On Adaptive Biotechnologies

Institutional investors and hedge funds have recently bought and sold shares of the company. Brighton Jones LLC lifted its holdings in shares of Adaptive Biotechnologies by 3.1% during the 3rd quarter. Brighton Jones LLC now owns 23,301 shares of the company’s stock valued at $349,000 after purchasing an additional 700 shares during the last quarter. Bouvel Investment Partners LLC boosted its holdings in Adaptive Biotechnologies by 2.2% in the third quarter. Bouvel Investment Partners LLC now owns 42,878 shares of the company’s stock worth $641,000 after acquiring an additional 904 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Adaptive Biotechnologies by 3.1% during the second quarter. China Universal Asset Management Co. Ltd. now owns 30,512 shares of the company’s stock worth $355,000 after acquiring an additional 910 shares during the last quarter. California State Teachers Retirement System grew its stake in shares of Adaptive Biotechnologies by 1.0% during the second quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock worth $1,145,000 after acquiring an additional 933 shares during the last quarter. Finally, Captrust Financial Advisors boosted its stake in Adaptive Biotechnologies by 7.6% in the 2nd quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock worth $184,000 after purchasing an additional 1,119 shares in the last quarter. 99.17% of the stock is owned by hedge funds and other institutional investors.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.